ALNY earnings call for the period ending December 31, 2019.
News & Analysis: Alnylam Pharmaceuticals
Shares of the genetic disease specialist were essentially flat in late afternoon trading.
All of the share price gains came after September -- and for good reason.
Patients who inherit life-threatening blood disorders have some important new treatment options.
What goes up must come down. But today's tumble means relatively little for investors with a long-term mindset.
The RNAi pioneer earned a surprise drug approval. It could have far-reaching implications for the company's future.
Investors were caught off guard when the genetic medicines company earned marketing approval for its second RNAi drug product sooner than expected.
Here's why the FDA recently approved five new drugs way ahead of schedule.
This biotech's impressed the FDA, but what about shareholders?
Alnylam Pharmaceuticals is coming of age.